Union européenne - français - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agents antithrombotiques - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Canada - français - Health Canada

abbott laboratories, limited - acide valproïque (divalproex de sodium) - comprimé (à libération prolongée) - 500mg - acide valproïque (divalproex de sodium) 500mg - miscellaneous anticonvulsants

Canada - français - Health Canada

omega laboratories limited - acide zolédronique (acide zolédronique monohydraté) - solution - 4mg - acide zolédronique (acide zolédronique monohydraté) 4mg - bone resorption inhibitors

Canada - français - Health Canada

omega laboratories limited - bromure de rocuronium - solution - 10mg - bromure de rocuronium 10mg - neuromuscular blocking agents

Canada - français - Health Canada

omega laboratories limited - phosphate de dexaméthasone (phosphate de dexaméthasone sodique) - solution - 10mg - phosphate de dexaméthasone (phosphate de dexaméthasone sodique) 10mg - adrenals

Canada - français - Health Canada

abbott laboratories, limited - dronabinol - capsule - 5mg - dronabinol 5mg - miscellaneous antiemetics

Canada - français - Health Canada

abbott laboratories, limited - dronabinol - capsule - 2.5mg - dronabinol 2.5mg - miscellaneous antiemetics

Canada - français - Health Canada

abbott laboratories, limited - acide valproïque (valproate de sodium) - liquide - 500mg - acide valproïque (valproate de sodium) 500mg - miscellaneous anticonvulsants

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - nitrofurantoïne 50 mg - gélule - 50 mg - nitrofurantoïne 50 mg - nitrofurantoin

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amdipharm ltd. - nitrofurantoïne 100 mg - gélule - 100 mg - nitrofurantoïne 100 mg - nitrofurantoin